merger « Science and Enterprise

Make me wanna shout ... #BillsMafia https://t.co/iF1vhKHXtu
about 2 hours ago
First of two podcasts with experiences of news photographers in the insurrection. Thanks @cherissmay for sharing yo… https://t.co/aCjPD6ct84
about 18 hours ago
Half or more of American adults express negative opinions about the way Covid-19 vaccines are distributed, accordin… https://t.co/9l2SUpW85u
about 24 hours ago
New post on Science and Enterprise: Infographic – US Public Down on Vaccine Rollout https://t.co/vegz3ihvIO #Science #Business
about 24 hours ago
We've written several times about Lander and his work, including companies he founded. ... Biden to Elevate Science… https://t.co/rWVGTa1gPL
about 1 day ago

Neuroscience Biotech Acquired in $770M Deal

By Alan, on December 17th, 2020%

A three year-old biotechnology company developing treatments for psychiatric and movement disorders is being acquired by global drug maker Novartis. . . . → Read More: Neuroscience Biotech Acquired in $770M Deal

Oral Drug Delivery Company Acquired in $1.8B Deal

By Alan, on November 6th, 2020%

Emisphere Technologies, developers of a process that makes biologic drugs available as oral medicines is being acquired by drug maker Novo Nordisk. . . . → Read More: Oral Drug Delivery Company Acquired in $1.8B Deal

Venture Rounds, IPOs, Mergers Vanish in Election Week

By Alan, on November 3rd, 2020%

Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week

Bayer Gains Gene Therapy Biotech in $4B Deal

By Alan, on October 26th, 2020%

Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders. . . . → Read More: Bayer Gains Gene Therapy Biotech in $4B Deal

Lilly Gains Neuro Disease Biotech in $1.36B Deal

By Alan, on October 15th, 2020%

Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders. . . . → Read More: Lilly Gains Neuro Disease Biotech in $1.36B Deal

Heart Disease Biotech Acquired in $13.1B Deal

By Alan, on October 5th, 2020%

A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion. . . . → Read More: Heart Disease Biotech Acquired in $13.1B Deal

Cancer Screening Analytics Company Acquired in $8B Deal

By Alan, on September 21st, 2020%

A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal

Gilead Acquires Cancer Therapy Biotech for $21B

By Alan, on September 14th, 2020%

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

Food Allergy Biotech Acquired for $2.6B

By Alan, on August 31st, 2020%

Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B

Sanofi Acquires Immune Disease Biotech in $3.7B Deal

By Alan, on August 17th, 2020%

A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi. . . . → Read More: Sanofi Acquires Immune Disease Biotech in $3.7B Deal

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise